pharmacogenomics
Castle Biosciences Q4 Revenues Jump 53 Percent as Firm Beats Analyst Expectations
Castle also reported full-year revenues at the top end of previously issued guidance and offered full-year 2023 guidance ahead of Wall Street expectations.
NewStem, MSK Innovation Hub Team to Validate Cancer Diagnostics Software Platform
The Israeli startup called this collaboration a necessary step toward commercializing its CE-marked NewStem Software Diagnostic Device for reducing oncology drug resistance.
The myPGx panel adds pharmacogenomics testing services from Veritas Genetics, a company the firm acquired earlier this year, to LetsGetChecked's portfolio.
UK's NICE to Accelerate Assessment of Genedrive Test
NICE plans to assess Genedrive's MT-RNR1 test for antibiotics-induced hearing loss in infants via a new program.
As part of the program, point-of-care tests sold by Genedrive and Genomadix will be assessed, as well as laboratory-developed tests used within the UK National Health Service.